The Biostatistics, Bioinformatics and Systems Biology (BBSB) Core 1. provides statistics and data analysis required by the Projects and Core to achieve their specific aims; 2. provides bioinformatics and systems biology expertise required for analysis of high-throughput assay data; 3. assists in the design and implementation of trials and studies arising from the ongoing research of the SPORE; 4. provides data management support for the Cores and Projects. The Core assists Project 1 with the development of high dimensional predictive models for early detection, and with the identification of further potential markers (e.g. autoantibodies) for improving panels available. The Core assists Project 2 with the design and analysis of in vitro and in vivo studies interrogating the interaction of DII4-Notch signaling, angiogenesis, and VEGF in ovarian cancer. The Core will provide assistance with the design and analysis of a Phase I clinical trial. The Core assists Project 3 with the characterization low grade tumor data from SNP arrays, expression arrays and mutation data measured on selected genes by direct sequencing. The Core assists with biomarker identification, sample size and power calculations, and with planning for a phase I clinical trial. The Core assists Project 4 with refining definitions for PISKness and BRCAness using data from several high-throughput assays, and with determining the extent to which these signatures are predictive of response in cell line and xenograft models. The Core is also providing assistance with the design of two Phase II trials involving targeted therapies. The Core assists Project 5 with the determination of the optimal dose, gene product, and combination with chemtherapy for treatment with Mesenchymal Stem Cells (MSCs). The Core will also assist with assessing effectiveness of MSC therapy and with the design of a Phase l/ll trial to identify an optimal biological dose with acceptable toxicity.
The BBSB Core provides support to the Projects and Cores of the SPORE. This support includes designing in vivo and in vitro experiments and analyzing results obtained, designing new clinical trials, assisting in the conduct of and analyzing results from ongoing trials, supplying analysis and interpretation of high-throughput assays, combining results across assays, and helping interpret results in terms of component pathways.
|Haemmerle, Monika; Stone, Rebecca L; Menter, David G et al. (2018) The Platelet Lifeline to Cancer: Challenges and Opportunities. Cancer Cell 33:965-983|
|Allen, Julie K; Armaiz-Pena, Guillermo N; Nagaraja, Archana S et al. (2018) Sustained Adrenergic Signaling Promotes Intratumoral Innervation through BDNF Induction. Cancer Res 78:3233-3242|
|Umamaheswaran, Sujanitha; Dasari, Santosh K; Yang, Peiying et al. (2018) Stress, inflammation, and eicosanoids: an emerging perspective. Cancer Metastasis Rev 37:203-211|
|Wang, Jue; Zhao, Wei; Guo, Huifang et al. (2018) AKT isoform-specific expression and activation across cancer lineages. BMC Cancer 18:742|
|Huang, Yan; Hu, Wei; Huang, Jie et al. (2018) Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer. Mol Cancer Ther 17:464-473|
|Yang, Hailing; Mao, Weiqun; Rodriguez-Aguayo, Cristian et al. (2018) Paclitaxel Sensitivity of Ovarian Cancer Can be Enhanced by Knocking Down Pairs of Kinases that Regulate MAP4 Phosphorylation and Microtubule Stability. Clin Cancer Res 24:5072-5084|
|Rhyasen, Garrett W; Yao, Yi; Zhang, Jingwen et al. (2018) BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitors. PLoS One 13:e0200826|
|Chen, Jian; Zaidi, Sobia; Rao, Shuyun et al. (2018) Analysis of Genomes and Transcriptomes of Hepatocellular Carcinomas Identifies Mutations and Gene Expression Changes in the Transforming Growth Factor-? Pathway. Gastroenterology 154:195-210|
|Sun, Chaoyang; Yin, Jun; Fang, Yong et al. (2018) BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency. Cancer Cell 33:401-416.e8|
|Hu, Xiaowen; Sood, Anil K; Dang, Chi V et al. (2018) The role of long noncoding RNAs in cancer: the dark matter matters. Curr Opin Genet Dev 48:8-15|
Showing the most recent 10 out of 648 publications